After the death, last December 21, a new-born, the national Agency of the Drug (MSNA) has decided “precautionary measure” of suspending the commercialization of Uvestérol D®. The infant had received the drug before being the victim of a cardio-respiratory arrest.
The MAN has committed, as a precautionary measure, a procedure for the suspension of the marketing of the Uvestérol D®. Only that product is affected by this action, not the other specialities of vitamin D.
For its part, the ministry in charge of Health, for the information of all families, just activate a toll-free information, available at 0800 636 636. He wished, however, to reassure the parents whose children have received the drug : “they will not be harmed “.
The mode of administration ?
Even if investigations are underway to determine the exact causes of the death of the infant, the department is already moving in a press release that ” it is the mode of administration, specific to the product that presents risk “.
Yet, in 2015, the Review of Prescribing reminded that discomfort, sometimes severe, attributable to the making of Uvestérol (D or A, D, E, C) are known since 1996. “This drug is administered into the infant’s mouth using a pipette. “And you continue,” over the years, various changes have been made to the medication and its pipette of directors. But there is no tangible element of the evaluation showing that these changes reduce the risk. There is no discomfort of this kind is described with the other specialties of vitamin D not associated (Zyma D®, or other). “
Recall that the first conclusions of the investigations conducted by the MSNA will be known in the coming days.